Global Public-Private Collaboration CARB-X Funds 50th Innovative Antimicrobial, Helps Repopulates Declining Antibiotic Pipeline

According to WHO, an estimated 700,000 people die each year worldwide from bacterial infections, including an estimated 23,000 people in the United States. Since BARDA founded CARB-X in 2016, this public-private partnership has become the world’s largest dedicated to early development of novel products to combat antibiotic resistant infections. To date, CARB-X has invested more than $150 million to accelerate the development of antibiotics, vaccines, diagnostics and other life-saving products to combat drug-resistant superbugs. “Antibiotic resistance is a real and serious threat to national security and public health,” said Rick Bright, PhD, HHS Deputy Assistant Secretary for Preparedness and Response and Director of BARDA. “CARB-X has generated valuable momentum in re-catalyzing the antibiotic pipeline. Reaching this milestone of supporting 50 innovative candidates in just three years is a testament to what can be achieved through public-private partnerships and to the power of diverse international coalitions working together to manage this urgent problem.”

Read News Release